Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocardial RNA Expression Changes Induced by Myosin Inhibitor Therapy in Obstructive Hypertrophic Cardiomyopathy (MyoRNA-oHCM)
jRCT1040250178Recruiting
- Sponsor
- Kanazawa University Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Kanazawa University Hospital. Primary endpoints: Myocardial bulk RNA sequencing profile, Single-nucleus RNA sequencing profile and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT1040250178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040250178.